Basiliximab: efficacy and tolerability in adults and children.
Transplant Proc
; 35(7): 2518-9, 2003 Nov.
Article
em En
| MEDLINE
| ID: mdl-14612000
UNLABELLED: An open, single arm, prospective clinical trial to assess the efficacy and safety of basiliximab (Simulect) combined with cyclosporine microemulsion (Neoral), steroids, and azathioprine was performed in four centers in Chile, two adult and two pediatric. The 23 patients who were enrolled were followed for 12 months. There were four acute rejection episodes (three adults and one child) and three graft losses (two adults and one child) during the study. Renal function in both adult and pediatric patients at 6 and 12 months was good. Basiliximab was well tolerated. The incidence of infections was low, with only one CMV infection. There were no deaths. CONCLUSIONS: The incidence of acute rejection episodes among renal allograft recipients treated with basiliximab is low, showing that the drug is well tolerated. In particular the number of CMV infections is extremely low.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Proteínas Recombinantes de Fusão
/
Transplante de Rim
/
Imunossupressores
/
Anticorpos Monoclonais
Tipo de estudo:
Clinical_trials
Limite:
Adult
/
Child
/
Humans
Idioma:
En
Revista:
Transplant Proc
Ano de publicação:
2003
Tipo de documento:
Article
País de afiliação:
Chile
País de publicação:
Estados Unidos